瑞格列奈联合二甲双胍治疗初诊2型糖尿病的临床疗效及安全性分析

Analysis of the Clinical Efficacy and Safety of Repaglinide Combined with Metformin in the Treatment of Newly Diagnosed Type 2 Diabetes

目的探讨瑞格列奈联合二甲双胍治疗初诊2型糖尿病的临床疗效及安全性。方法选择2020年1—12月在该院治疗的92例初诊糖尿病患者作为研究对象,46例接受二甲双胍治疗的患者纳入对照组,46例接受瑞格列奈联合二甲双胍治疗的患者纳入观察组,比较两组患者治疗前与治疗后4个月血糖指标、治疗有效率与不良反应发生率的差异。结果两组患者治疗前FPG、2 hPG、HbAlc差异无统计学意义(P>0.05);观察组治疗后FPG、2 hPG、HbAlc分别为(6.3±1.2)mmol/L、(8.4±2.5)mmol/L、(6.5±1.4)%,优于对照组(7.1±1.9)mmol/L、(9.7±3.2)mmol/L、(7.1±1.6)%,差异有统计学意义(P<0.05);观察组治疗有效率为95.7%,高于对照组82.6%,差异有统计学意义(P<0.05)。观察组与对照组低血糖反应、胃肠道反应、肝功能损害发生率分别为4.4%、4.4%、2.2%与2.2%、6.5%、0.0%,两组不良反应发生率差异无统计学意义(P>0.05)。结论瑞格列奈联合二甲双胍治疗初诊2型糖尿病效果优于单纯二甲双胍治疗,不增加不良反应发生率。

Objective To investigate the clinical efficacy and safety of repaglinide combined with metformin in the treatment of newly diagnosed type 2 diabetes. Methods 92 newly diagnosed diabetic patients treated in the hospital from January to December 2020 were selected as the research object, 46 patients received metformin treatment as the control group, 46 patients received repaglinide combined with metformin treatment as the observation group, and compared the blood glucose index, treatment effective rate and adverse reaction rate of patients before treatment and 4 months after treatment. Results There was no statistically significant difference in FPG, 2 hPG and HbAlc between the two groups of patients before treatment,the difference was not statistically significant(P>0.05). After treatment in the observation group, FPG, 2 hPG, and HbAlc were(6.3±1.2) mmol/L,(8.4±2.5) mmol/L,(6.5±1.4)%, respectively,which were better than those of the control group(7.1±1.9) mmol/L,(9.7±3.2) mmol/L,(7.1±1.6)%,the difference was statistically significant(P<0.05). The effective rate of treatment in the observation group was 95.7%, which was higher than 82.6% in the control group,the difference was statistically significant(P<0.05). The incidence of hypoglycemia,gastrointestinal reactions, and liver damage in the observation group and the control group were 4.4%, 4.4%, 2.2%and 2.2%, 6.5% and 0.0%, respectively. There was no statistically significant difference in the incidence of adverse reactions between the two groups(P >0.05). Conclusion The effect of repaglinide combined with metformin in the treatment of newly diagnosed type 2 diabetes is better than that of metformin alone, and does not increase the incidence of adverse reactions.